Genomic and phenotypic heterogeneity in prostate cancer

MC Haffner, W Zwart, MP Roudier, LD True… - Nature Reviews …, 2021 - nature.com
From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

High-risk prostate cancer—classification and therapy

AJ Chang, KA Autio, M Roach III, HI Scher - Nature reviews Clinical …, 2014 - nature.com
Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease.
However, the current definitions of high-risk prostate cancer include a heterogeneous group …

Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management

JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Clinically localized prostate cancer: AUA/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up

JA Eastham, GB Auffenberg, DA Barocas… - Journal of …, 2022 - journals.lww.com
Purpose: The summary presented herein represents Part II of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing principles of …

[HTML][HTML] Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019

S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell… - European urology, 2020 - Elsevier
Background Innovations in treatments, imaging, and molecular characterisation in advanced
prostate cancer have improved outcomes, but there are still many aspects of management …

[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …

S Gillessen, A Bossi, ID Davis, J de Bono, K Fizazi… - European urology, 2023 - Elsevier
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer

F Abdollah, RJ Karnes, N Suardi… - Journal of clinical …, 2014 - ascopubs.org
Purpose The role of adjuvant radiotherapy (aRT) in treating patients with pN1 prostate
cancer is controversial. We tested the hypothesis that the impact of aRT on cancer-specific …

Development and internal validation of a novel model to identify the candidates for extended pelvic lymph node dissection in prostate cancer

G Gandaglia, N Fossati, E Zaffuto, M Bandini… - European urology, 2017 - Elsevier
Background Preoperative assessment of the risk of lymph node invasion (LNI) is mandatory
to identify prostate cancer (PCa) patients who should receive an extended pelvic lymph …

More extensive pelvic lymph node dissection improves survival in patients with node-positive prostate cancer

F Abdollah, G Gandaglia, N Suardi, U Capitanio… - European urology, 2015 - Elsevier
Background The role of extended pelvic lymph node dissection (ePLND) in treating prostate
cancer (PCa) patients with lymph node invasion (LNI) remains controversial. Objective The …

[HTML][HTML] A DROP-IN gamma probe for robot-assisted radioguided surgery of lymph nodes during radical prostatectomy

P Dell'Oglio, P Meershoek, T Maurer, EMK Wit… - European Urology, 2021 - Elsevier
Abstract Background The DROP-IN gamma probe was introduced to overcome the restricted
manoeuvrability of traditional laparoscopic gamma probes. Through enhanced …